EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum

Evan R Lombardo iD, Robert S Pijewski iD, Jake T Lustig iD, Zaenab Dhari, Anirudhya Lahiri, Lucille E Papile iD, Erica R Lavoie iD, Vanessa M Scanlon iD, Jenna M Bartley iD, Stephen J Crocker iD

Proceedings of the National Academy of Sciences · 24.03.2026 · 123 (12)

DOI: 10.1073/pnas.2524897123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.03.2026. Verfasst von Evan R Lombardo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, University of Connecticut School of Medicine, Farmington, CT 06030. Hauptthemen laut MEDLINE: Oligodendroglia, Corpus Callosum, Demyelinating Diseases, Dasatinib. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NINDS NIH HHS, HHS | NIH (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address disease progression. However, the effects of senolytics, a class of drugs which selectively ablate senescent cells, on the central nervous system are largely unknown. Here, we examined the effects of senolytic treatment on myelination and oligodendrocyte function in vivo using C57BL6/J mice and in vitro using primary rat oligodendrocyte cultures. Initial data showed that naïve young (3 to 4 mo) and aged (22 mo) C57BL6/J mice treated with dasatinib and quercetin (D+Q) developed significant demyelination compared to vehicle-treated controls, though no cell death was observed in the brain. In vitro, oligodendrocyte progenitor cells treated with D+Q in differentiation media exhibited significantly reduced myelin basic protein protein and morphological complexity, also without inducing cell death. Bulk RNA sequencing and ingenuity pathway analysis of D+Q treated oligodendrocytes identified differentially expressed genes associated with endoplasmic reticulum stress. These data suggest that D+Q evokes the unfolded protein response in oligodendrocytes, causing oligodendrocyte dysfunction and myelination failure. Due to the resemblance between oligodendrocytes treated with D+Q and those found in MS lesions, D+Q treatment offers a potential method to model an aspect of oligodendrocyte dysfunction relevant to MS. Therefore, understanding the mechanism by which D+Q perturb oligodendrocyte function may provide insight into some of the pathological features contributing to disease progression in MS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligodendrogliaCorpus CallosumDemyelinating DiseasesDasatinibSenotherapeuticsAnimalsMiceRatsQuercetinMice, Inbred C57BLMyelin SheathFemaleCells, CulturedAgingEndoplasmic Reticulum StressMultiple Sclerosis

Stichwörter der Autor:innen

agingdemyelinationmyelinoligodedrocytesenescence

Substanzen

DasatinibQuercetinSenotherapeutics

Autor:innen und Institutionen

  • Department of Neuroscience, University of Connecticut School of Medicine, Farmington, CT 06030.
  • Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health of New England, Hartford, CT 06112.
  • Department of Rehabilitative Medicine, Frank H. Netter School of Medicine at Quinnipiac University, North Haven, CT 06518.
  • Center for Regenerative Medicine and Skeletal Development, University of Connecticut School of Dental Medicine, Farmington, CT 06030.
  • Center on Aging, University of Connecticut School of Medicine, Farmington, CT 06030.
  • Department of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030.

ORCID-Profile: Evan R Lombardo, Robert S Pijewski, Jake T Lustig, Lucille E Papile, Erica R Lavoie, Vanessa M Scanlon, Jenna M Bartley, Stephen J Crocker

Förderung

  • NIAID NIH HHS
  • NINDS NIH HHS
  • HHS | NIH (NIH)

Zitieren

APA

Lombardo, E. R., Pijewski, R. S., Lustig, J. T., Dhari, Z., Lahiri, A., Papile, L. E., Lavoie, E. R., Scanlon, V. M., Bartley, J. M., & Crocker, S. J. (2026). Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum. Proceedings of the National Academy of Sciences, 123(12). https://doi.org/10.1073/pnas.2524897123

Vancouver

Lombardo ER, Pijewski RS, Lustig JT, Dhari Z, Lahiri A, Papile LE, et al. Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum. Proceedings of the National Academy of Sciences. 2026;123(12). doi:10.1073/pnas.2524897123

BibTeX
@article{Lombardo2026,
  author = {Lombardo, Evan R and Pijewski, Robert S and Lustig, Jake T and Dhari, Zaenab and Lahiri, Anirudhya and Papile, Lucille E and Lavoie, Erica R and Scanlon, Vanessa M and Bartley, Jenna M and Crocker, Stephen J},
  title = {Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {12},
  doi = {10.1073/pnas.2524897123}
}
Kostenlos starten →